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Introduction
Mosaicism in genetics is the presence in an individual of 
two or more cell lines that are genotypically distinct and 
are derived from a single zygote. Therefore, in mosaic 
body two or more distinct genotypes exist in different 
cell populations (Fig. 1). Germline (gonadal) mosaicism 
refers to genetic variation in the genomes of germline cells 
within an individual. In somatic mosaicism, in accordance 
with the newest research findings, mutation originated in 
somatic cell (somatic mutation) in early embryonic devel-
opment may be found in both somatic and germline cells of 
this organism and may also lead to genotypic and possibly 
phenotypic heterogeneity within and between tissues (Hol-
stege et al. 2014). Sporadic de novo mosaicism appears in 
the particular individual only. The parental mosaicism may 
manifest in the form of changes in the parent offspring’ 
phenotype as a result of both types somatic or germinal 
mutations. Current studies suggest that both sporadic and 
parental mosaicism may be more common than previously 
suspected (Donkervoort et al. 2015). Also, the apparently 
de novo mutation in the patient might be indeed a conse-
quence of somatic mosaicism identified in somatic tis-
sues of unaffected parents of this patient (Campbell et al. 
2014a).
In general, in somatic mosaicism, different mosaic ratio 
may be found in patient’ distinct body tissues. Constitu-
tional somatic mosaicism refers to the presence of normal 
and abnormal cells with a mutation recognized with the 
constant mosaic ratio in various tissues in the examined 
individual.
Mosaicism arises as a result of genetic alterations of 
different type and size, including single nucleotide vari-
ants (SNVs), copy number variants (CNVs), and simple or 
complex chromosomal rearrangements. These alterations 
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may be present only in a subset of somatic or germ cells in 
the individual’ body. The issues when each mutation was 
acquired and how the analyzed clones expanded during 
a lifetime remain to be elucidated (Holstege et al. 2014). 
However, based on the recent research findings and clini-
cal diagnostics data, it is suggested that the occurrence of 
mosaicism events is underestimated as the genotypes in the 
mosaic ratio often stay unrevealed, especially in the low-
grade mosaicism.
Somatic mutations are frequent events 
during early development and aging
Somatic mutations commonly occur during cell division; 
therefore, frequently dividing cells are more prone to 
acquire somatic mutations than tissues that rarely divide 
(Youssoufian and Pyeritz 2002). Epithelial cells, hemat-
opoietic cells, and male germ cells are examples of repeat-
edly dividing cell types which are vulnerable to somatic 
mutations leading to phenotype alterations (Campbell et al. 
2014a, b). In general, every round of mitotic cell division is 
expected to generate several somatic mutations (Youssou-
fian and Pyeritz 2002; Seshadri et al. 1987). It was assumed 
that the effects of somatic mutations were restricted to 
the lifetime of the individual and were not transmitted to 
the progeny (De 2011). The current research revealed that 
somatic mutation acquired in the early stage of embryonic 
postzygotic development might cause mosaicism in the 
parent who later transmits the mutation to the offspring 
through the germ cell (Campbell et al. 2014a).
Mosaicism has been reported in as high as 70 and 90 % 
of cleavage- and blastocyst-stage embryos derived from 
in vitro fertilization, respectively (Taylor et al. 2014). 
Postzygotic chromosome loss, chromosome gain and 
mitotic nondisjunction were observable in some cells creat-
ing mosaic events in early embryos (Daphnis et al. 2005; 
Taylor et al. 2014).
Very interested study model to assess somatic varia-
tion occurring during early embryonic development is this 
involving monozygotic twins. Among other findings, twins 
discordant for somatic mosaicism for aneuploidy of chro-
mosomes X and Y (Razzaghian et al. 2010) and different 
copy number profiles changing during aging in monozy-
gotic twins have been identified (Dumanski 2008). Also, 
it has been detected that deletions, inversions and translo-
cations of genetic material were more common in aging 
mice compared with younger ones (Dollé and Vijg 2002) 
causing in aging tissues increasingly heterogeneous gene 
expression.
Also, mitochondria accumulate altered sequence 
variants during the lifetime. Mitochondrial genetics is 
different from the Mendelian in many aspects, including 
the uniparental inheritance of disease mutations and the 
presence of many copies of the genome within a single cell. 
Mitochondrial DNA (mtDNA) mutations are an important 
cause of inherited diseases. Mitochondrial diseases 
display pathological phenotypes because of the mixture of 
Fig. 1  Various distribution of mutant cells in the human body and 
different types of mosaicism in particular individuals. In somatic 
mosaicism (a) mutant cells may appear with different mosaic ratio in 
patient’ distinct body tissues but not in gonads. As gonadal mosaicism 
refers to genetic variation in the genomes of germline cells within an 
individual it may be recognized in testes (b) and ovaries. Examples 
of low-grade (c) and medium-grade (d) somatic mosaicism in endo-
derm derivatives (epithelial lining of digestive tract and respiratory 
tract) point to quantitative difference in mosaic ratio. Constitutional 
somatic mosaicism (e) refers to the presence of normal and abnormal 
cells with a mutation recognized with the constant mosaic ratio (or 
almost unchanging mosaic ratio) in various tissues in the examined 
individual
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mutant versus wild-type mtDNA, known as heteroplasmy. 
Similarly to somatic DNA mutation, the mtDNA alteration 
may occur in a part of mitochondria only. Disease causing 
heteroplasmy can be identified at several levels, including 
within the multiple copies of mtDNA per mitochondria, 
between healthy and diseased mitochondria within a cell, 
or among mosaic cellular subpopulations assembled within 
tissues (Clifford et al. 2013).
Methods in the detection of the degree of hetero-
plasmy are similar to mosaicism identification in nuclear 
DNA. Increasing sensitivity of genomic technologies 
supports mitochondrial heteroplasmy assessment at the 
genome-wide scale (Li et al. 2010; Sosa et al. 2012; Li 
and Stoneking 2012). A number of studies using the new-
est approaches allowed detection of medium- and high-fre-
quency heteroplasmy. It has been found that ~25–65 % of 
the general population had at least one heteroplasmy across 
the entire mitochondrial genome (Li et al. 2010; Sosa et al. 
2012).
Therefore, in the optimal mosaicism search scenario, 
mosaicism occurrence in the cells in early development 
stage and in the terminally differentiated tissues, and in 
both nuclear DNA and mtDNA should be considered and 
investigated to characterize entirely mosaicism phenotypic 
consequences in the examined individual. Still, in labora-
tory practice usually one or two tests are performed, fre-
quently chosen to be used based on incorrect assumptions 
as discussed later in this paper.
There are numerous endogenous molecular mechanisms 
that generate somatic mutations and cause mosaicism func-
tioning during the lifetime of an individual, whereas others 
(such as Alu and L1 retrotransposition) are likely to have 
specific temporal patterns (De 2011). The mechanisms give 
rise to genetic sequence variants of predictable or unknown 
phenotypic consequences. DNA damage by reactive oxy-
gen species, replication error by DNA polymerase and erro-
neous DNA repair, DNA polymerase slippage and trinu-
cleotide repeat expansion, both short and long interspersed 
nuclear element (Alu and L1) retrotransposition, fork stall-
ing and template switching (FoSTeS), non-homologous end 
joining (NHEJ), non-allelic homologous recombination 
(NAHR), micro-homology-mediated replication-depend-
ent recombination (MMRDR), micro-homology-mediated 
break-induced repair (MMBIR), reversion mosaicism, and 
loss or gain of chromosomes of ploidy have been reported 
as involved in mosaicism etiology, as reviewed in detail in 
the paper by De (2011). Exogenous factors such as nicotine 
and alcohol usage, and UV exposure may also be involved 
in somatic mutation formation.
To emphasize the high incidence of somatic muta-
tions, revertant mosaicism should be mentioned. Revertant 
mosaicism is a naturally occurring phenomenon relatively 
common in genetic skin diseases (Pasmooij et al. 2012). In 
revertant mosaicism, cells carrying disease-causing muta-
tions co-exist with cells in which the inherited mutation 
is genetically corrected by a spontaneous event (Pasmooij 
et al. 2012). It has been found that in vivo reversion of 
somatic cells involved the skin, the liver and the hemat-
opoietic cells, thus the tissues with high cell proliferation 
rates (Davis et al. 2010). Also, revertant mosaicism has 
been noticed repeatedly within the same patient and in vivo 
reversion could involve multiple cell lineages or be limited 
to a particular cell clone (Lai-Cheong et al. 2011).
All those data indicate that number of somatic mutations 
may be higher than anticipated in both healthy and changed 
by disease tissues. As a consequence, somatic mosaicism 
incidence would be presumably underestimated.
Harmless nature of somatic mutations in healthy 
human tissues
Several reports revealed the increase in occurrence of 
somatic copy number changes with age in several tissues 
in mice and in peripheral blood in cancer-free humans as 
discussed in the paper by Holstege et al. (2014). Recently, 
biological material derived from a healthy person of 
extreme age, a 115-year-old woman, was examined to test 
the hypothesis that the number of single nucleotide somatic 
mutations might increase with age (Holstege et al. 2014). 
The examined woman had no symptoms of hematologi-
cal illnesses, and autopsy showed that she did not suffer 
from vascular- or dementia-related pathology. She had 
breast tumor surgery at age 100 and died 15 years later of 
a gastric tumor that metastasized into her abdomen (Hol-
stege et al. 2014). She has never received mutation induc-
ing chemotherapy. DNA was isolated from several tissues 
that were collected during autopsy: whole blood, brain 
(occipital cortex), artery (media and endothelium), kidney 
(renal pyramid and minor calyx), heart, liver, lung, spleen, 
aorta, and the gastric tumor that she died of. DNA was 
also isolated from the breast tumor that was removed at 
age 100 (Holstege et al. 2014). The prevalence and types 
of single nucleotide and small insertion/deletion muta-
tions that are somatic within the healthy blood genome 
were assessed. Since cells in occipital brain tissue rarely 
divide after birth (Spalding et al. 2005), it was expected 
that these cells did not acquire many somatic mutations, so 
that DNA isolated from occipital brain tissue could serve 
as a control sequence of the germline genome (Holstege 
et al. 2014). Consequently, DNA sequence extracted from 
peripheral blood was compared with DNA from the brain 
tissue. Based on deep whole-genome sequencing, approxi-
mately 450 somatic mutations in the nonrepetitive genome 
within the healthy blood cells were found (Holstege et al. 
2014). Detected and confirmed somatic SNVs and indels 
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were mostly novel (Holstege et al. 2014). None of the 376 
somatic mutations that mapped to coding regions were pre-
dicted to have a deleterious effect on protein function by 
the SIFT and PolyPhen algorithms. Furthermore, none of 
the mutations were previously associated with clinical out-
come. Therefore, as somatic mutations overlapped with 
functional elements similar to nonpathogenic dbSNP vari-
ants, but did not with disease-associated variants, the data 
supported their harmless nature (Holstege et al. 2014). 
However, there are also contradictory data indicating the 
damaging effect of somatic mutations, as discussed below.
Impact of mosaicism on the epigenome
Somatic mutations can possibly affect the epigenetic pat-
terns and levels of gene expression, and then the pheno-
types of cells. Also, regardless of the sequence alterations 
in nuclear and/or mitochondrial DNA, abnormal DNA 
methylation, as an example of the so-called epi-mutations, 
is frequently observed (Holstege et al. 2014; Berko et al. 
2014; Laurentino et al. 2015).
Likewise to genetic variation, changed methylation pat-
terns may occur in a subset of cells only. In the body of 
115-year-old woman, mutations occurred in cells with a 
stem cell-like methylation signature (Holstege et al. 2014). 
The authors of that study suggested that a subset of the 
somatic mutations have resulted from the spontaneous 
deamination of methylated cytosines, forming a thymine at 
that location. They found that 62 of the 376 somatic muta-
tions mapped in putatively methylated CpG sites, indicat-
ing a significantly increased mutation-likelihood at CpG 
loci (P value <1 × 10−6) (Holstege et al. 2014).
In a paper by Berko et al., mosaic epigenetic dysregula-
tion of ectodermal cells in autism spectrum disorder (ASD) 
was revealed (Berko et al. 2014). To explore whether 
advanced maternal age involves hidden aneuploidy or epi-
genetic dysregulation leading to ASD in the offspring, a 
homogeneous ectodermal cell type from 47 individuals 
with ASD compared with 48 typically developing con-
trols born to mothers of ≥35 years, using a quantitative 
genome-wide DNA methylation assay, was tested (Berko 
et al. 2014). The results pointed to the presence of a mosaic 
subpopulation of epigenetically dysregulated, ectodermally 
derived cells in subjects with ASD (Berko et al. 2014). The 
results indicated that epigenetic dysregulatory mechanisms 
might complement and interact with DNA mutations in the 
pathogenesis of the disorder (Berko et al. 2014).
In the latest report, epigenetic germline mosaicism 
in infertile men was assessed (Laurentino et al. 2015). 
As abnormal sperm parameters and male infertility have 
been previously linked to aberrant methylation patterns of 
imprinted genes in sperm DNA, the authors of this study 
investigated whether spermatozoa were a homogeneous 
cell population regarding DNA methylation of imprinted 
genes (Laurentino et al. 2015). Pyrosequencing-based 
oligo-sperm methylation assay (OSMA) and deep bisulfite 
sequencing were used to measure DNA methylation of 
the KCNQ1OT1, MEST, H19 and MEG3 genes. The study 
revealed that normozoospermic samples had a homogenous 
pattern of DNA methylation, whereas oligoasthenozoosper-
mic samples contained discrete populations of spermatozoa 
with either normal or abnormal methylation patterns, indi-
cating epigenetic mosaicism (Laurentino et al. 2015).
Further research is necessary to assess interactions 
between somatic and epigenetic mutations and phenotypi-
cal consequences of those relations, especially if the muta-
tions are present in the mosaic pattern.
Mosaic chromosomal abnormalities
Chromosomal abnormalities include an altered number of 
chromosomes, simple or complex chromosomal rearrange-
ments involving deletions, duplications, insertions, inver-
sions and translocations, and small supernumerary marker 
chromosomes. Mosaicism is frequently associated with 
those chromosomal mutations. It has been found that the 
ratio of mosaic cells may influence the severity of pheno-
typic changes (Kaminker et al. 1985; Liehr et al. 2013).
An altered number of chromosomes most commonly 
arises because of an error in chromosome distribution at 
cell division. The gains or losses of entire chromosomes 
may occur as a result of nondisjunction, anaphase lagging 
of both an autosome and a sex chromosome (Coonen et al. 
2004) and chromosome gain referred to as endoreplication 
(Taylor et al. 2014).
Examples of syndromes associated with mosaicism are 
Trisomy 8 syndrome and Trisomy 9 mosaic syndrome. 
Most of the patients with Trisomy 8 syndrome have been 
mosaics of trisomy C-group autosome/normal (Kurtyka 
et al. 1988). In many cases, normal karyotype from cul-
tured leukocytes but trisomy 8 in skin fibroblast cells was 
observed. There appears to be a lack of correlation between 
the phenotype and the percentage of trisomic cells (Smith 
2006). In contrast to Trisomy 8 syndrome, in Trisomy 9 
mosaic syndrome the incidence and severity of malforma-
tions and intellectual deficiency correlate with the percent-
age of trisomic cells in the different tissues (Kaminker et al. 
1985; Smith 2006).
In addition to errors in chromosome number, 
chromosomal imbalance can result in shorter loss or 
gain of genetic information. In Pallister–Killian mosaic 
syndrome, the chromosomal change responsible for 
the disorder typically occurs as a random event during 
the formation of reproductive cells in a parent of the 
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affected individual. As an error in cell division called 
nondisjunction, the isochromosome 12p is created and the 
child may have two normal copies of chromosome 12 along 
with an isochromosome 12p. As cells divide during early 
development, some cells lose the isochromosome 12p, 
while other cells retain the abnormal chromosome, causing 
mosaicism. Almost all cases of Pallister–Killian mosaic 
syndrome are caused by mosaicism for an isochromosome 
12p (Izumi and Krantz 2014).
Chromosomal deletions and/or duplications or 
triplications of different sizes are being identified. Large 
copy number alterations, in size up to ~10 Mb, often arise as 
a result of erroneous non-allelic homologous recombination 
and non-homologous end joining (Dittwald et al. 2013). 
Also, in somatic mosaicism’ etiology, a role of interspersed 
nuclear elements-1 (LINE-1 or L1) has been established with 
L1 retrotransposons active during embryonic development 
causing copy number alterations (van den Hurk et al. 2007).
One more example of chromosomal abnormality is 
somatic mosaicism in cases with small supernumerary 
marker chromosomes (sSMC) (Liehr et al. 2013). Somatic 
mosaicism was found in slightly more than 50 % of sSMC 
carriers, in different mosaic rates, which might go below 
5 % of the studied cells (Liehr et al. 2013). Even though in 
the majority of the patients somatic sSMC mosaicism had 
no direct clinical effect, there were also cases with altered 
clinical outcomes due to mosaicism (Liehr et al. 2013).
Since the genotype–phenotype correlations are diffi-
cult to be established in patients with constitutional chro-
mosomal rearrangements (Gajecka et al. 2007), different 
mosaic rates of chromosomal abnormalities may addition-
ally complicate the prediction of clinical outcome. Both 
recurrent and nonrecurrent chromosomal aberrations usu-
ally cause a range of phenotypic features observed in the 
studied patient groups (Gajecka et al. 2007, 2008a). How-
ever, in the laboratory practice, cases with high-grade 
mosaicism, with mutation in 70–99 % of cells, are not 
separated from the completely constitutional, meaning 
observed in 100 % of body cells, aberrations. In the com-
ing years, with improved mosaicism identification proto-
cols the phenotypic differences among patients with appar-
ently the same mosaic chromosomal aberration but diverse 
mosaic ratio would be probably explained.
Unrevealed low‑grade mosaicism
High-grade mosaicism, in rate of 70 % and higher, usually 
stays unrecognized and then is not evaluated in clinical 
practice. In contrast, medium- and low-grade mosaicism, 
if suspected, usually is carefully assessed. Types of the 
tested biological materials and applied identification and 
verification methods constitute main factors influencing 
the mosaicism detection, especially of the low grade, with 
mosaic rates below 5 % of the studied cells. Besides the 
extensive effort and continuous progress, identification of 
mosaics remains very challenging in clinical diagnostics 
and research laboratories.
Mosaic chromosomal abnormalities have been reported 
to represent 8 % of abnormal laboratory chromosomal 
microarray analysis (CMA) results, suggesting that mosaic 
findings may be more common than previously thought 
(Ballif et al. 2006). Low-level mosaicism may be missed by 
standard cytogenetic techniques such as G-banded karyo-
type. The abnormality may not be reported if the percent-
age of abnormal cells does not meet the laboratory’s thresh-
old for reporting. When mosaicism is suspected, in addition 
to standard protocols, extra cells may be analyzed as well 
various tests performed including fluorescence in situ 
hybridization (FISH) analysis using specific probes. Even 
when mosaicism is strongly suspected by the clinician, the 
putative genetic cause is usually unknown (Cheung et al. 
2007), causing difficulties in the further genetic investiga-
tion. Because of relatively low resolution of cytogenetic 
methods, the submicroscopic abnormalities may remain 
undetected. While the analyses are frequently performed on 
the cultured cells, the detection of mosaicism event can be 
even more complicated by a loss or reduction of the abnor-
mal cell line during cell culture protocols carried in vitro in 
laboratory (Ballif et al. 2006; Theisen et al. 2009). Those 
aspects are crucial to be considered especially if low-grade 
mosaicism is expected. Application of CMA in diagnostics 
significantly improved mosaicism identification process in 
patients presenting with chromosomal abnormalities (Wap-
ner et al. 2012). Still, proper design of the test with mul-
tiple control probes and repeats, its sufficient resolution 
and the appropriate biological material tested are critical to 
solve the diagnostic problem.
Mutations much smaller in size, including indels or 
SNVs, are not detectable using conventional cytogenetic or 
molecular cytogenetic techniques. As a solution, molecu-
lar biology methods, including various PCR techniques, 
Sanger sequencing, MLPA, array SNP, the next-generation 
sequencing (NGS) and others, are implemented to iden-
tify, categorize, confirm or corroborate mosaicism findings. 
Despite numerous techniques available to be applied in the 
search, low-grade mosaicism remains a difficult issue in 
both clinical diagnostics and research.
Tested material influences the mosaicism detection 
rate
Various biological materials may be tested in mosaicism 
investigation. Primarily, low invasive procedures are 
recommended in the sample collection process. Peripheral 
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blood samples (PBSs), lymphoblastoid cell lines, amnion 
or chorion cells, fibroblasts, myocytes and cells derived 
from other tissue biopsies, buccal tissue, saliva, and nails 
are the most frequently used.
Mosaicism detection is always correlated with the muta-
tion identification per se. Targeted material, containing the 
causing mutation, would be optimal for testing and always 
better than the most accessible one. As already mentioned, 
frequently dividing cells would be the examples of mate-
rial to test or verify somatic mosaicism. In research, rarely 
dividing cells after birth, including occipital brain tissue, 
would constitute a control material in comparison analyses 
(Spalding et al. 2005; Holstege et al. 2014). In contrast, in 
constitutional somatic mosaicism the most accessible tissue 
sample will be appropriate for testing.
Germinal mosaicism is difficult to assess, especially if 
maternally originated mutation is suspected as the causative 
alteration, as eggs from ovaries are difficult to be derived, 
besides the aspect of highly invasive procedure.
Usually the type of material is chosen based on diag-
nostic technique to be applied. Of the almost 400 different 
human body tissues, generally only one tissue, i.e., blood, 
amnion or chorion cells, or fibroblasts is studied cytoge-
netically (Liehr et al. 2013). This fact generates a risk of 
inaccuracy in mosaicism assessment. Based on the chosen 
material, a simple sample or even multiple samples, the 
real rate of somatic mosaicism in any studied individual is 
impossible to be precisely recognized (Liehr et al. 2013). 
Since somatic mutations at the same time may occur in 
different tissues and in distinct body’ sites with different 
mosaic ratio (Fickelscher et al. 2007; Liehr et al. 2011), 
without extensive sampling the obtained results would be 
correct for the specific analyzed samples only. For exam-
ple, deep resequencing of a mutation on a next-generation 
sequencer identified very-low-grade somatic mosaicism in 
the mother: 0.4, 1.1, and 8.3 % in the saliva, blood leuko-
cytes, and nails, respectively (Miyatake et al. 2014) indi-
cating various mosaic rates in the different tested tissues. 
This is why in the present-day genetic counseling the fact 
of mosaicism rather than mosaic ratio is further character-
ized. Still, the mosaic ratio is estimated to collect data for 
further genotype–phenotype correlations. In contrast to 
the latter research example, in a patient with breast cancer, 
very similar level of mutation (~5 %) in the tested tissues 
(in leukocytes, buccal tissue and normal breast tissue DNA) 
was identified and the authors concluded that the patient 
had a low-grade constitutional somatic mosaicism resulted 
in ~47 % mutation level in tumor tissue (Friedman et al. 
2015).
At this point, it is worth to add that there is a growing 
concern in the field about whether some CNVs categorized 
as germline-acquired mutations in biobanks are actually 
somatically acquired alterations, especially when the 
germline mutations were inferred by testing only one tissue 
as pointed by De (2011).
The newest evidence has shown that acquired somatic 
mutations might remain specific during aging in the origi-
nal sites of appearance only. In the 115-year-old woman, 
somatic mutations detected in blood were not detected in 
the breast cancer that patient had at age 100 nor in the gas-
tric tumor she had at age 115 or other native tissues. This 
indicates that the somatic mutations in blood were not 
derived from tumor cells at the time of her death (Holstege 
et al. 2014). In that study, validation panel was also used 
to test samples derived from aorta, artery (endothelium), 
heart, and kidney (renal pyramid) tissues derived from 
115-year-old woman’ body (Holstege et al. 2014). None 
of the confirmed somatic mutations detected in blood were 
detected in these tissues, and only an occasional muta-
tion detected in blood could be detected in artery (media), 
kidney (minor calyx), liver, and spleen tissues (Holstege 
et al. 2014). On the other side, in accordance with current 
knowledge (Schwarzenbach et al. 2011), mutations identi-
fied in the tumor samples would be probably detectable in 
blood samples by the assessment of the cell-free circulating 
DNA. However, this analysis has not been performed.
Contamination is always the issue in daily laboratory 
practice. Again in the study of the 115-year-old woman, 
almost all identified somatic mutations were detected in 
DNA derived from the lung tissue (Holstege et al. 2014). 
The authors of that study suggested that the DNA isolated 
from lung tissue was apparently contaminated with blood 
DNA due to a vast leukocyte presence in the lung tis-
sue (Holstege et al. 2014). One more example of sample 
contamination would be buccal tissue contaminated with 
saliva obtained during the oral swab procedure. In contrast 
to common opinion that buccal epithelial cells are mostly 
found in saliva, it has been reported that up to 74 % of the 
DNA in saliva comes from white blood cells (Thiede et al. 
2000).
In the era of constant progress in technology used in 
clinical diagnostics and research, it is crucial to adjust the 
tested material to the detection technique. Sdano et al. 
reported on three patients in which CMA technology 
detected mosaicism with a larger percentage of abnormal 
cells in buccal tissue compared to blood leukocytes (Sdano 
et al. 2014). The authors recommended to clinicians to 
consider buccal samples as a primary sample for certain 
genetic studies (such as CMA) or to consider additional 
testing using DNA from buccal samples in patients for 
whom a genetic etiology was suspected but a diagnosis 
has not been achieved using DNA from blood leukocytes 
(Sdano et al. 2014). Blood leukocytes have long been 
the “gold standard” material for cytogenetic and other 
analyses. While the DNA derived from PBSs was usually 
tested in CMA approaches, the mentioned study and other 
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current reports (Miyatake et al. 2014; Braunholz et al. 
2015) evidently question the recommendations of standard 
diagnostic protocols.
Lymphoblastoid cell lines are controversial diagnostic 
material, very valuable to repeat the original experiments 
especially if the derived biological sample was used in the 
analyses but causing difficulties in result interpretation if 
unforeseen events took place during the cell line establish-
ment process. Lymphoblastoid cell lines are commonly 
used in research laboratories. However, they frequently 
undergo both the introduction of large mosaic abnormali-
ties and the loss of biological mosaicism due to a tendency 
toward clonality (Shirley et al. 2012; Migeon et al. 1988). 
The culturing process for routine chromosome analysis can 
complicate the detection of mosaicism since the normal 
cell line may have a growth advantage in the culture (Sdano 
et al. 2014). Even ‘simple’ cultured cells, proceeded with-
out a step of immortalization, may be significantly altered 
and generate erroneous results in cytogenetic testing (Ballif 
et al. 2006; Theisen et al. 2009). Moreover, the immortali-
zation process may cause not only mosaic ratio fluctuations 
but even additional chromosomal abnormalities, including 
terminal deletions (Gajecka and Shaffer 2007, unpublished 
data). It has been repeatedly confirmed, using FISH and 
sequence specific PCR techniques, that immortalization 
process generated terminal deletion of 1q44 chromosomal 
region in patients with 1p36 microdeletion syndrome, sig-
nificantly affecting research outcomes when FISH probes 
corresponding to 1q44 region were used as control probes 
in the 1p36 microdeletion syndrome study (Gajecka and 
Shaffer 2007, unpublished data; Gajecka et al. 2006a).
A choice of appropriate tissue from a variety of biologi-
cal materials to be tested seems to be even more difficult if 
numerous diverse techniques are available to be applied in 
the mosaicism detection, as discussed below.
Applied methods impact the mosaicism 
identification
Chromosomal mosaicism is identified using various cytoge-
netics techniques, such as trypsin treatment and Giemsa 
staining, and synchronized culture techniques, to allow 
for the identification of individual chromosomes. Molecu-
lar cytogenetic techniques, like metaphase, interphase 
and fiber FISH and comparative genomic hybridization 
(CGH) as well as array comparative genomic hybridization 
(aCGH), allow for the detection of more subtle changes in 
copy number in the genome. In addition, various PCR tech-
niques and sequencing of chromosomal regions containing 
the rearrangement breakpoints and junctions may be use-
ful for characterization of specific rearrangements (Gajecka 
et al. 2006a, b, 2008b; D’Angelo et al. 2009; Rosenfeld 
et al. 2011; Midro et al. 2014). Depending on the probe and 
the clinical question, these techniques offer advantages in 
clinical situations including expected mosaicism.
Next-generation sequencing has revolutionized the field 
of genetics and currently provides opportunities to assess 
mosaicism, including the low-grade mosaicism. The high‐
throughput nature of NGS technology allows for very 
high fold coverage of sequenced fragments and detection 
of low levels of mutated variants among wild-type alleles. 
Through the high sensitivity of this method, researchers 
are able to discover mosaic mutations often regarded as 
background noise and missed in Sanger sequencing (Roh-
lin et al. 2009). Recently, the targeted high sensitive NGS 
technique allowed for the detection of mosaic mutations 
present in only a small fraction of the blood cells in patients 
with brain malformations (Jamuar et al. 2014). The 63 % of 
these mosaic mutations were undetectable with the direct 
Sanger sequencing method but were validated through sub-
cloning and subsequent sequencing of the subcloned DNA 
(Jamuar et al. 2014). NGS method was also used in the sin-
gle-cell whole-genome sequencing in more than 200 single 
cells, including ~160 neurons from non-pathological and 
pathological human brains (Cai et al. 2014). In that study, 
mosaic clonal CNVs were identified in normal lympho-
blast cells and neurons. These results are largely in agree-
ment with a previously reported study (McConnell et al. 
2013) and showed that NGS technologies were suitable for 
identification of mosaic CNVs. Taken together, NGS is an 
important diagnostic tool for detecting somatic mosaicism. 
However, a relatively high cost of an experiment may be a 
major limitation for large-scale application of this method 
in diagnostic laboratory.
Discussed below are different mosaicism investigations 
with various outcomes. The six examples, summarized in 
Table 1, were intended to show the complexity of mosai-
cism detection and complementarity of different methods, 
including NGS and other techniques, in the mosaicism 
study.
In addition to NGS technologies, other methods are 
implemented in mosaicism identification including Sanger 
sequencing, high-resolution melting (HRM) analysis, 
allele-specific PCR, pyrosequencing, SNaPshot and immu-
nohistochemistry. In the NGS era, those techniques would 
be especially useful in preliminary screening and result 
verification.
Sanger sequencing has been frequently used in 
mosaicism investigations. Limitations of Sanger sequencing 
in molecular diagnostics were currently shown in a study 
on Cornelia de Lange syndrome (CdLS) (Braunholz et al. 
2015). The genetic cause of CdLS is a mutation in one of 
the five associated genes (NIPBL, SMC1A, SMC3, RAD21, 
and HDAC8) accounting for about 70 % of cases and the 
genetic cause of the remaining 30 % of the patients with 
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a clinical diagnosis of CdLS is unknown (Braunholz et al. 
2015). Braunholz et al. collected buccal mucosa (BM) 
samples of patients that were negative for mutations in the 
known CdLS genes testing DNA derived from the blood. 
Three mosaic NIPBL mutations by high-coverage gene 
panel sequencing approach that was undetected by classical 
Sanger sequencing of BM DNA were identified (Braunholz 
et al. 2015). All mutations were confirmed with a primer 
extension-based method developed for the analysis of 
SNPs (SNaPshot fragment analysis) using DNA from BM, 
urine, and fibroblast samples. The respective mutations 
were not detected in PBSs. Finally, in fibroblast samples 
from all three patients, Sanger sequencing could identify 
all the mutations (Braunholz et al. 2015) as summarized in 
Table 1 (Example 1).
At present, Miyatake et al. explored whether low-grade 
somatic mosaicism was detectable by HRM analysis 
(Miyatake et al. 2014). Low-grade somatic mosaicism in a 
suspected carrier, rather than germline mosaicism, has been 
revealed using various techniques (Miyatake et al. 2014), 
as shown in Table 1 (Example 2). The HRM has been sug-
gested to be one of the more sensitive methods in mosaic 
mutation identification (Ihle et al. 2014). HRM analysis 
was performed using DNA from unaffected individuals 
(controls), the affected siblings, the father (all DNA derived 
from blood), and the mother [DNA derived from the nails, 
which showed the highest rate of mosaicism (8.3 %) by the 
NGS, targeted resequencing]. The melting curves of the 
two affected siblings were aberrant and were called mutant, 
while those of the parents were called normal. There-
fore, HRM analysis could not detect the 8.3 % mosaicism 
(Miyatake et al. 2014). In contrast, allele-specific PCR was 
sufficiently sensitive to detect mosaicism in PBS derived 
from the mother in mosaic rate of 1.1 % (Miyatake et al. 
2014). The authors of this study concluded that using the 
conventional mosaicism approach, the mother might have 
been judged to have germline mosaicism and, therefore, 
NGS should be the first choice for detecting very-low-
grade somatic mosaicism (Miyatake et al. 2014).
In other current report, sensitivity, specificity and 
feasibility of six different methods for the detection 
of BRAF mutations (p.V600E and non-p.V600E) 
were evaluated. Comparison of HRM analysis, 
pyrosequencing, allele-specific PCR, targeted NGS and 
immunohistochemistry (IHC) to conventional Sanger 
sequencing was performed (Ihle et al. 2014) as presented 
in Table 1 (Example 3). Targeted NGS was shown to be 
able to detect somatic BRAF mutations down to 2 % allele 
frequency, demonstrating the increased sensitivity of this 
method compared with HRM (limit 6.6 % allele frequency), 
pyrosequencing (limit 5 % allele frequency), and Sanger 
sequencing (limit 6.6 % allele frequency) (Ihle et al. 2014). 
However, it is necessary to mention that assessed mutations 
were known as causative in melanoma and were previously 
extensively evaluated. Assessment of unknown mosaicism 
event without specific mutation indication in clinical 
diagnostics is definitely much more challenging.
As buccal cells are becoming increasingly utilized for 
clinical analyses and are proving to have many advantages, 
clinical utility of CMA analysis using DNA derived from 
buccal cells in free patients was investigated (Sdano et al. 
2014), as shown in Table 1 (Example 4). Patient 1 was 
determined to be mosaic for trisomy 21 with the abnormal-
ity present in 15–20 % of the buccal sample (BS) (using 
MCA) and 4 % of the cultured blood leukocyte (CL) sam-
ple (using interphase and metaphase FISH) (Sdano et al. 
2014). In patient 2, the second CMA experiment, per-
formed on a BS, showed an estimated 20 % mosaicism 
for tetrasomy 12p, consistent with a diagnosis of Pallister–
Killian syndrome. Retrospective analysis of the results of 
the first CMA experiment (DNA from PBS used) showed 
no evidence of a copy number gain of 12p. Therefore, the 
latest finding was only detectable through analysis of the 
buccal specimen (Sdano et al. 2014). In patient 3, stand-
ard G-banded karyotype analysis (with increased number 
of analyzed cells) and CMA revealed three cell lines 45,X 
(in ~45 % of BS and 6 % of CL), 46,XX, and the indeter-
minate cell line [either (46,X,idic (X) (p11.21) or 46,X,del 
(X) (p11.21)] in ~15–20 % of BS and not seen in CL while 
the normal chromosome complement was present in ~40 % 
of BS and 94 % of CL (Sdano et al. 2014). These cases 
confirm that CMA analysis can detect mosaicism and that 
uncultured buccal samples may be the most suitable sample 
for at least the first line of genetic analysis, especially in 
the case of mosaicism suspicion (Sdano et al. 2014). Those 
three cases indicate the need to properly choose both the 
optimal biological material to be tested and one or more 
appropriate techniques in the mosaicism search. Applied 
CMA platform (CytoScanHD®, Affymetrix) included 
probes for single nucleotide polymorphic (SNP) identifica-
tion and copy number responsive probes allowing for both 
single nucleotide variants and copy number changes iden-
tification, increasing confidence in detection of mosaicism.
In mosaicism identification, numerous PCR techniques 
are implemented, including real-time PCR, long-range 
PCR, and individual-specific breakpoint PCR. Quantita-
tive analysis of the ratio of mutant versus wild-type allele 
(COL6A1, COL6A2, and COL6A3) in genomic DNA from 
various tissues, including blood, cultured dermal fibro-
blasts, and saliva, was performed in four families with col-
lagen type 6-related dystrophies and myopathies (COL6-
RD) (Donkervoort et al. 2015). Applied real-time PCR 
revealed differences between mosaicism ratio in tissues 
tested in parents carrying the causative mutations (Donk-
ervoort et al. 2015), as presented in Table 1 (Example 5). 
Consistent with somatic mosaicism, parental samples had 
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lower ratios of mutant versus wild-type allele compared 
with the fully heterozygote offspring (Donkervoort et al. 
2015).
Pathogenic BRCA1 mutations are usually inherited. 
Constitutional low-level BRCA1 mosaicism has never been 
reported until the current paper published by Friedman et al. 
(2015). Using NGS of a cancer gene panel of germline and 
tumor DNA in a patient with early onset of breast cancer, 
constitutional de novo mosaicism (~5 %) for a pathogenic 
(c.1953dupG; p.Lys652Glufs*21) BRCA1 mutation was 
detected in leukocytes, buccal tissue and normal breast 
tissue DNA, with ~47 % mosaic ratio of the mutation in 
tumorous breast tissue (Friedman et al. 2015), as indicated in 
Table 1 (Example 6). In previous reports of somatic BRCA1 
mutations, the mutant allele was identified in the tumor cells 
only, as pointed in the paper by Friedman et al. (Friedman 
et al. 2015). Although a few cases of de novo constitutional 
BRCA1 or BRCA2 mutations have previously been described, 
most were detected in a heterozygous form in constitutional 
DNA and were not mosaic (Friedman et al. 2015). In the 
study by Friedman et al., mosaic signal of 4.9–6.8 % was 
reproducibly detected in all samples of leukocytes, buccal 
tissue and normal breast. Therefore, the consistency of 
the load of c.1953dupG mutation across different tissue 
types suggested that this event occurred early in embryonic 
development and this idea was further supported by the 
lack of the same mutation in maternal constitutional DNA 
confirmed using deep sequencing (Friedman et al. 2015).
Campbell et al. assessed somatic mosaicism for 
transmitted mutations among parents of children with 
the simplex genetic disease (Campbell et al. 2014a). 
Individual-specific breakpoint PCR was applied to assess 
100 families with children previously found to be affected 
by genomic disorders due to rare deletion CNVs originally 
determined to be de novo by clinical analysis of parental 
DNA (Campbell et al. 2014a). Performing highly sensitive 
individual-specific breakpoint PCR, they identified four 
cases of low-grade somatic mosaicism for the transmitted 
CNVs in DNA isolated from PBS (Campbell et al. 2014a). 
The authors concluded that the technique of individual-
specific breakpoint PCR was more sensitive, less expensive, 
required less infrastructure and was less invasive than a 
skin biopsy in the CNV mosaicism detection (Campbell 
et al. 2014a). However, to design the final PCR the 
individual-specific breakpoint should be identified earlier 
in the affected individual to test the parents.
To detect large rearrangements, multiplex ligation-
depending probe amplification (MLPA) is often used. It has 
been shown that MLPA was less sensitive in detecting low-
grade somatic mosaicism than FISH or a mutation-specific 
PCR test (van Veghel-Plandsoen et al. 2011). MLPA of 
TSC2 gene showed a pattern consistent with a duplication of 
sequence fragment containing exons 15–26. Using MLPA 
protocol, the duplication was hardly detectable in father’ 
DNA (van Veghel-Plandsoen et al. 2011). Long-range PCR, 
followed by sequencing of the abnormal PCR product, 
resulted in the identification of the mutation and the ratio 
of the mutant versus the wild-type fragment was lower 
compared with the proband, indicating that the father was 
a somatic mosaic for the mutation (van Veghel-Plandsoen 
et al. 2011). The duplication-specific PCR showed that 
about 30 % of the father’s leukocytes carried the duplication 
and this technique was able to detect a mosaic pattern of 
about 10 % (van Veghel-Plandsoen et al. 2011). A mosaic 
pattern of about 40 % could be detected by MLPA analysis, 
which explains why the 30 % mosaicism could not be 
detected by MLPA. To investigate the sensitivity of the 
MLPA in detecting deletions, material derived from patients 
with a total NF1 deletion, previously identified using FISH, 
was assessed. It was possible to detect a deletion present 
in 22–30 % of the cells. These results indicate that mosaic 
duplications are harder to be detected than deletions using 
MLPA method (van Veghel-Plandsoen et al. 2011). Still, 
the size of the rearrangement, the probe density, and DNA 
quality could influence the mosaic mutation detection (van 
Veghel-Plandsoen et al. 2011).
Array-based comparative genomic hybridization 
(aCGH), as a one type of the CMA, has been frequently 
used in chromosomal abnormality investigations, especially 
if other routine techniques including subtelomere FISH did 
not reveal aberration. In a patient with a small (1.52 Mb), 
interstitial deletion in 1p36 region de novo rearrangement 
was identified using bacterial artificial chromosomes and 
oligonucleotide microarrays in the patient. Metaphase 
FISH with probes corresponding to the deletion region 
was performed and excluded the deletion in the parents. 
However, when a second child was born in this family 
performed CMA showed apparently the same interstitial 
deletion (Gajecka et al. 2010). As a germline mosaicism 
was suspected in the mother, the deletion breakpoints 
and the sequence junction in the rearrangement were 
identified using molecular biology techniques in the older 
sibling. Next, using breakpoint specific PCR with primers 
unique for the two interstitial deletion breakpoints, the 
PCR product containing the junction sequence fragment 
was amplified using DNA from blood samples derived 
from both siblings. That result confirmed that the same 
rearrangement occurred in both siblings and that the 
germline mosaicism in the mother was the possible 
pattern of the deletion occurrence (Gajecka et al. 2010). 
Currently, with the newest evidence concerning low-grade 
mosaicism in the healthy parents of the affected offspring, 
this research example would be a subject to suspect a 
low-grade mosaicism in the mother. However, based on 
the breakpoint-specific PCR performed with blood DNA 
samples of both parents, no amplification of the junction 
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fragment was obtained, again suggesting germline rather 
than somatic mosaicism (Gajecka and Shaffer 2014, 
unpublished data).
Currently, microarray analyses, also known as molecu-
lar karyotyping (or CMA), are widely used in clinical diag-
nostics. Wapner et al. evaluated the accuracy, efficacy, and 
incremental yield of CMA as compared with karyotyping 
for routine prenatal diagnosis (Wapner et al. 2012). It was 
shown that microarray analysis was equivalent to a stand-
ard karyotype analysis for the prenatal diagnosis of com-
mon aneuploidies. The used array was designed to maxi-
mize the detection of well-characterized microdeletions 
and duplications but also included oligonucleotides to 
identify additional chromosomal imbalances (Wapner et al. 
2012). Preferentially uncultured samples were proceeded 
to avoid, among others, the artifacts of cell and tissue cul-
ture (Wapner et al. 2012). It was noted that in 4391 samples 
available for microarray analysis 58 had mosaic karyotype 
results and those mosaic cases were excluded from the 
CMA. Microarray analysis identified all the aneuploidies 
detected by means of standard karyotyping. In addition, 
eight of these cases, all from uncultured chorionic-villus 
samples, were mosaic on the microarray and could repre-
sent mosaicism not detected on karyotyping (Wapner et al. 
2012). Also, of the three marker chromosomes detected on 
karyotyping, two were identified on microarray (Wapner 
et al. 2012).
Single-cell array-based comparative genomic hybridiza-
tion (single-cell aCGH) is an example of successful devel-
opment of high-resolution full-genome analysis methods 
applicable to single cells. For example, Jacobs et al. studied 
the genetic content of 92 individual human cells, including 
fibroblasts, amniocytes and embryonic stem cells (hESCs), 
using single-cell array-based comparative genomic hybridi-
zation (aCGH) (Jacobs et al. 2014). They found that human 
somatic and embryonic stem cell cultures show significant 
fractions of cells carrying unique megabase-scale chro-
mosomal abnormalities, establishing genetic mosaics that 
could not have been detected by conventional cytogenetic 
methods (Jacobs et al. 2014).
Also SNP arrays are utilized in mosaicism investigations, 
including patients with pregnancies at increased risk for 
the common aneuploidies (Van Opstal et al. 2015). SNP 
array allows for detection of submicroscopic chromosome 
abnormalities, presented also in the form of low-level 
mosaicism (Van Opstal et al. 2015).
High-resolution SNP microarray generates a huge 
number of data. This fact remains an issue in the proper 
diagnostics process. Since enhanced statistical analyses 
may probably resolve the problem, various methods are 
implemented in bioinformatics pipelines. The parent-of-
origin-based detection (POD) method for chromosomal 
abnormality detection in trio-based SNP microarray data is 
an example of the solution showing the robustness across 
multiple types of Illumina microarray chips (Baugher 
et al. 2013). triPOD is a fast, efficient, multi-threaded 
software program for chromosomal abnormality detection 
in offspring using SNP array data from parent–child trios. 
The implementation of the POD method greatly increases 
the ability to detect mosaic abnormalities in SNP array data 
(Baugher et al. 2013). Although triPOD was developed for 
microarray data from the Illumina platform, automated 
adjustments for sample-specific levels of quality and 
variation allow for application to other platforms from 
which SNP-specific genotypes, allelic ratios, and copy 
number data can be derived (Baugher et al. 2013). Also, an 
adaptation of the POD method for analysis of mosaicism in 
next-generation sequence data is anticipated (Baugher et al. 
2013).
Sometimes mosaicism is investigated with other 
than discussed above techniques. Suspicion of revertant 
mosaicism in the clinic can be investigated through skin 
biopsy analysis, typically using immunohistochemistry 
and/or transmission electron microscopy (Lai-Cheong 
et al. 2011). Also, real-time PCR and flow cytometry 
were applied in the mosaicism detection in patients with 
autosomal dominant hyper-IgE syndrome (Hsu et al. 
2013).
How multistep is mosaicism detection process?
Inconsistencies between mosaicism detection techniques 
and variety in the downstream analyses may complicate 
the comparison of the clinical diagnostic’ or research 
outcomes. Mosaicism identification is usually a multi-
step process, extensive, expensive and time consuming. 
Table 1 presents mosaicism detection process in different 
cases suspected to be mosaic. Usually more than one tech-
nique is used to recognize mosaicism. Then, additional 
method, usually different than the first one used, is applied 
to confirm the feature. In the case of performed qualita-
tive assessment only the subsequent test will be done to 
estimate the mosaic ratio. Finally, with the clinical and 
diagnostic data, genotype–phenotype correlation will 
be assessed to discuss and/or predict mosaicism clinical 
consequences.
There is no gold standard test in mosaicism detection. 
While the improvement in mosaicism detection points 
to NGS technologies as the most promising method, 
there are some hesitations and exemptions. For example, 
it is postulated that the only reliable approach to detect 
sSMC present in the low-level mosaic pattern is banding 
cytogenetics (Liehr et al. 2013). Also, in the case of Patient 
3 (Sdano et al. 2014; Table 1, Example 4), the complexity 
of mosaicism events was finally revealed using CMA, with 
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both copy number and SNP probes. However, only trained 
in G-banded karyotype analysis cytogeneticist could verify 
the finding (Sdano et al. 2014). Moreover, it is worth to 
point that methods already established and functioning 
in the laboratory ale less error prone comparing to novel 
technologies to be implemented. Also, while the NGS 
technologies for themselves are user friendly, the following 
bioinformatics analyses are too complex to be performed 
in a regular diagnostic laboratory. A solution would be to 
use experience of laboratories specialized in particular 
mutation detection. Still, relatively high cost of both NGS 
experiments and bioinformatics analyses may be a major 
limitation for large-scale application of NGS in diagnostic 
laboratory.
Mosaicism and genetic counseling
Mosaicism can complicate clinical diagnosis and genetic 
counseling. Mosaic phenotypes may have incomplete syn-
dromic features, which may stay unnoticed, especially in a 
low-grade mosaicism. The recurrence risk for unaffected 
parents who have an affected child and are considering 
a pregnancy may be influenced by the frequency of the 
mosaic mutation, the severity of the phenotype conferred 
by mosaicism, the type of mutational mechanism, or the 
sex and age of the mosaic parent (Lupski 2013; Campbell 
et al. 2014b).
Mutation load in the material tested does not neces-
sarily correlate with the severity of disease as shown in 
the study by Donkervoort et al. (2015). A patient had 
the highest mutation load tested but showed the mildest 
phenotype, or vice versa the mosaic mutation was virtu-
ally undetectable in certain tissues (blood and saliva) in a 
clearly affected patient who tested positive in fibroblasts 
(Donkervoort et al. 2015). Choosing a single tissue only 
to be examined, there is always a possibility that higher 
levels of somatic mosaicism might be present in tissues 
derived from other cell lineages, but these were not ana-
lyzed, frequently due to unavailability of other tissues 
(Donkervoort et al. 2015).
Being currently revealed, low-grade somatic mosaicism 
appears to be a factor frequently causing diseases. Carriers 
of mosaic mutations may be at risk for abnormal pregnancy 
outcomes including offspring with the phenotype 
caused by the mutation in the form of a dominant allele. 
Those findings have important implications for genetic 
counseling and for understanding patterns of recurrence 
in transmission genetics. When two or more affected 
children are born to apparently unaffected parents, 
germline mosaicism is suspected. Identified mutation in 
the offspring suggests that dominant mutation appeared 
as recessive inheritance. However, with growing evidence 
of low-grade somatic mosaicism, without evaluation 
in somatic cells of the parents and/or the germ cells the 
diagnosis will be uncompleted. Consequently, regardless 
of mosaicism type, whether the parent has germline or 
somatic mosaic, he or she is at risk for a recurrence of 
another child with the disease. The risk ratios remain to 
be elucidated, although integrated probabilistic modeling 
of gametogenesis allowed predicting that mutations in 
parental blood increase recurrence risk substantially 
more than parental mutations confined to the germline 
(Campbell et al. 2014b).
Startling are the results in the newest report about low-
level constitutional mosaicism identified in a patient with 
breast cancer. Identified low-level constitutional somatic 
mosaicism in the BRCA1 (mutation c.1953dupG) indicated 
that the mutations recognized apparently in tumors only 
might be in fact present in low frequency in all body 
tissues as a constitutional genomic feature. As Sanger 
sequencing is the most frequently used method to screen 
BRCA1 gene in patients and individuals in risk of cancer, 
this technique would miss the majority of BRCA1 low rate 
mosaic mutations. Then, deep sequencing seems to be an 
optimal technique to screen this gene. Also, based on this 
example, it appears that constitutional mosaicism, similarly 
to constitutional heterozygous mutation in the carriers, 
should be screened and the carriers should be counseled for 
contralateral breast cancer, ovarian cancer and cancer risks 
for their offspring (Friedman et al. 2015).
As already mentioned, both low-grade somatic mosai-
cism and low-grade constitutional somatic mosaicism may 
occur early in embryonic development. Both low-grade 
somatic mosaicism and low-grade constitutional somatic 
mosaicism are comparable in one important diagnostic 
aspect: both types may be undetectable using DNA from 
PBS by Sanger sequencing. As different tissues should be 
tested to distinguish between the types, multiple samples 
are necessary to be proceeded. Although NGS technolo-
gies allow for low-grade mosaicism detection, a number 
of material samples to be tested per one patient are limited 
because of the high cost. Compared to targeted NGS, tar-
geted Sanger sequencing is a low cost technique even if 
several samples from different body sites from one patient 
would be examined. Therefore, the solution would be to 
modify protocols including as an obligatory additional 
material in the form of buccal swabs, saliva, and/or nails 
for DNA extraction, and then fibroblast and other tissues, if 
necessary to verify the results.
The need to revise protocols of clinical diagnostics in 
various diseases has been already expressed in the diagnos-
tic field as shown in examples of mosaicism investigation 
discussed in this paper in which an issue of appropriate 
biological material to be tested was highlighted. Although 
blood leukocytes have long been considered the “gold 
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standard” sample for genetic testing, there were significant 
benefits to examine additionally other tissues. Study by 
Braunholz et al. revealed the high proportion of a mosaic 
NIPBL mutation in patients with a typical CdLS pheno-
type that were mutation negative in previous conventional 
Sanger sequencing approaches of DNA from blood or even 
BM tissue (Braunholz et al. 2015). The authors recom-
mended adding BM as tested material and highlighted the 
need for use of highly sensitive technologies in molecular 
diagnostic of CdLS to improve genetic diagnosis and coun-
seling of patients and their families (Braunholz et al. 2015). 
Also in the report of somatic mosaicism for dominant col-
lagen 6 mutations, it was suggested that parental mosaicism 
may be more common than previously suspected in COL6-
RD (Donkervoort et al. 2015). The authors concluded that 
caution is required, as low levels of somatic mosaicism 
may not be detectable by standard genetic sequencing and 
pure germline mosaicism will not be detectable by testing 
of specimen types routinely available to diagnostic labora-
tories (Donkervoort et al. 2015).
Future directions
As NGS technologies constitute a promising 
methodological solution in mosaicism detection in the 
coming years, revisions in current diagnostic protocols are 
necessary to increase the detection rate of the unrevealed 
mosaicism events. In the NGS era, the apparently de novo 
mutations will be identified, in some percentage of cases, 
as a consequence of mosaicism occurred in the previous 
generation of the proband. Also, with various tissue 
samples tested per one individual mosaics even with low 
level of the mutation will be detected and the findings will 
allow for better genotype–phenotype correlations and more 
precise clinical diagnosis.
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